AGC
HRTX icon

Alden Global Capital’s Heron Therapeutics HRTX Stock Holding History

Alden Global Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-65,935
Closed -$864K – 7
2016
Q4 		$864K Buy
+65,935
New +$1.03M 0.3% 10

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Alden Global Capital's HRTX Position: Q1 2017 in Review

Alden Global Capital sold out of Heron Therapeutics (HRTX) in Q1 2017, closing a stake of 65,935 shares — an estimated $864K sold.

Alden Global Capital first reported a position in HRTX in Q4 2016 and held it in 1 quarter. The position peaked at $864K in Q4 2016. 100 funds tracked by Wall St. Rank hold HRTX as of Q1 2017.

  • Alden Global Capital reported no remaining Heron Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Alden Global Capital sold 65,935 Heron Therapeutics shares in Q1 2017, an estimated $864K.
  • Alden Global Capital first reported a position in Heron Therapeutics in Q4 2016 and held it in 1 quarter.
  • Alden Global Capital's Heron Therapeutics position peaked at $864K in Q4 2016.
  • 100 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2017.

Based on Alden Global Capital's 13F filing for Q1 2017, filed 11 May 2017.